• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Construction of non-clinical model corresponding to the metastatic urothelial carcinoma classified based on immune environment and molecular diagnosis

Research Project

Project/Area Number 17K16776
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Urology
Research InstitutionUniversity of Tsukuba

Principal Investigator

Kawahara Takashi  筑波大学, 医学医療系, 助教 (50758919)

Project Period (FY) 2017-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords膀胱癌 / がん免疫環境 / FGF-FGFRシグナル / 体細胞変異 / 分子分類 / 腫瘍内免疫環境 / 癌 / 尿路上皮癌 / 免疫環境 / 分子診断
Outline of Final Research Achievements

To elucidate the relationship between somatic mutations and tumor immune environment in bladder cancer, we analyzed bladder cancer tissues of 103 bladder cancer patients. We compared the relationship tumor characteristics with tumor immune environment. There were less CD8 positive infiltrating cells in FGFR3 mutation than in FGFR3 wild cases. There were more CD8 positive cells in TP53 mutation than TP53 wild cases. In molecular subtype, there were few CD8 positive infiltrating cells in basal type than in luminal type. Next, focusing on FGFR signals, FGFR3 expression was frequently found in low grade and low stage, and FGFR1 expression was in high grade and high stage. FGFR1 overexpression case showed high infiltration of CD8 positive T cells. We found that somatic mutations, molecular subtype and different activation of FGFR signals have different immune environments in bladder cancer.

Academic Significance and Societal Importance of the Research Achievements

近年膀胱癌でも免疫チェックポイント阻害剤が臨床応用されているが腫瘍内免疫環境の状態によって同薬剤の反応性が異なることが示されている。しかし、がん細胞の遺伝子変異や分子分類での腫瘍内免疫環境の関連は明らかとなっていない。今回の研究では体細胞変異および分子分類と腫瘍内免疫環境との関連に着目し、膀胱癌においてFGFR3遺伝子に変異を有する患者さんでは腫瘍細胞への免疫細胞浸潤が少なくTP53遺伝子に変異を有する患者さんでは腫瘍細胞への免疫細胞浸潤が多いことがわかった。また分子分類の違いにより免疫細胞浸潤が異なることを明らかとした。これらの結果は膀胱癌の個別化医療に向けての指標となることが期待される。

Report

(3 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • Research Products

    (2 results)

All 2019 2018

All Presentation (2 results)

  • [Presentation] FGFRシグナルの活性化機序により膀胱癌の腫瘍内免疫環境が異なる2019

    • Author(s)
      河原貴史、小島崇宏、黒部匡広、志賀正宣、田中建、神鳥周也、根来宏光、河合弘二、西山博之
    • Organizer
      第28回泌尿器科分子・細胞研究会
    • Related Report
      2018 Annual Research Report
  • [Presentation] Germline TP53 codon72 is associated with FGFR3 and RAS mutation and FGF signals in bladder cancer2018

    • Author(s)
      河原貴史、小島崇宏、木村友和、河合弘二、西山博之
    • Organizer
      第77回癌学会
    • Related Report
      2018 Annual Research Report

URL: 

Published: 2017-04-28   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi